[en] Background
Somatostatin analogs (SSAs) are first-line medical therapy for the treatment of acromegaly and neuroendocrine tumors that express somatostatin receptors (SSTR). Somatostatin suppresses secretion of a large number of hormones through the stimulation of the five SSTR. However, unbalanced inhibition of secretion as observed with the highly potent SSAs pasireotide causes hyperglycaemia mainly by inhibiting insulin secretion. In contrast, AP102 a new SSAs has neutral effect on blood glucose while suppressing GH secretion. Our objective was to establish the cellular effects of AP102 on SSTR2 and SSTR5 that may explain the differences observed between AP102 and other SSAs.
Methods
We compared the binding and agonist activity of AP102 with somatostatin-14, octreotide and pasireotide in HEK293 cells transfected with human SSTR2 and SSTR5 receptors. SSAs signal transduction effects (cAMP concentrations) were measured in forskolin-treated cells in the presence of SSAs. Proliferation and apoptotic effects were determined and binding assays were performed using 125I- somatostatin-14.
Results
AP102 has comparable affinity and agonist effect to octreotide at SSTR2 (IC50's of 112 pM and 244 pM, respectively; EC50's of 230 pM and 210 pM, respectively) in contrast to pasireotide that exhibits a 12–27 fold higher IC50 (3110 pM) and about 5-fold higher EC50 (1097 pM). At SSTR5, AP102 has much higher affinity and stimulating effect than octreotide (IC50's of 773 pM and 16,737 pM, respectively; EC50's of 8526 pM and 26,800 pM), and an intermediate affinity and agonist effect between octreotide and pasireotide. AP102, octreotide and pasireotide have variable anti-proliferative effects on HEK cells transfected with SSTR2 and SSTR5.
Conclusion
AP102 is a new SSA that better reduces signaling at SSTR2 than SSTR5 and prevents cell proliferation at both receptors. The euglycaemic effect of AP102 observed in preclinical studies may be related to this intermediate agonistic potency between pasireotide and octreotide at SSTR2 and SSTR5.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Streuli, Jeremy
Harris, Alan G.
Cottiny, Cecilia
Allagnat, Florent
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Grouzmann, Eric
Abid, Karim
Language :
English
Title :
Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors
Allagnat, F., Klee, P., Cardozo, A.K., Meda, P., Haefliger, J.A., Connexin36 contributes to INS-1E cells survival through modulation of cytokine-induced oxidative stress, ER stress and AMPK activity. Cell Death Differ. 20:12 (2013 Dec), 1742–1752, 10.1038/cdd.2013.134.
Bousquet, C., Puente, E., Buscail, L. et al., Antiproliferative effect of somatostatin and analogs. Chemotherapy 47:Suppl. 2 (2001), 30–39.
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., Weckbecker, G., SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146:5 (2002), 707–716.
Buscail, L., Estève, J.P., Saint-Laurent, N. et al., Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 92:5 (1995), 1580–1584.
Colao, A., Auriemma, R.S., Pivonello, R., The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19:2 (2016 Apr), 210–221, 10.1007/s11102-015-0677-y.
Daly, A.F., Sumeray, M., The dual SSTR2/5 specific somatostatin analog, AP102, does not affect glucose metabolism in diabetic ZDF rats: a comparative 14-day infusion study versus pasireotide. 15th International Pituitary Congress, Orlando, USA, March 29–31, 2017 (Abstract HT1).
Eigler, T., Ben-Shlomo, A., Somatostatin system: molecular mechanisms regulating anterior pituitary hormones. J. Mol. Endocrinol. 53:1 (2014 Aug), R1–19, 10.1530/JME-14-0034.
Eisenhofer, G., Tischler, A.S., de Krijger, R.R., Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr. Pathol. 23:1 (2012 Mar), 4–14, 10.1007/s12022-011-9188-1.
Franscini, L.C., Vazquez-Montes, M., Buclin, T., Perera, R., Dunand, M., Grouzmann, E., Beck-Popovic, M., Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: relevance to the diagnosis of neuroblastoma. Pediatr. Blood Cancer 62:4 (2015 Apr), 587–593, 10.1002/pbc.25385.
Georgieva, I., Koychev, D., Wang, Y. et al., ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology 91:2 (2010), 121–130.
Grant, M., Alturaihi, H., Jaquet, P., Collier, B., Kumar, U., Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22:10 (2008 Oct), 2278–2292.
Katznelson, L., Laws, E.R. Jr., Melmed, S., Molitch, M.E., Murad, M.H., Utz, A., Wass, J.A., Endocrine society acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99:11 (2014 Nov), 3933–3951, 10.1210/jc.2014-2700.
Körner, M., Specific biology of neuroendocrine tumors: peptide receptors as molecular targets. Best Pract. Res. Clin. Endocrinol. Metab. 30:1 (2016 Jan), 19–31, 10.1016/j.beem.2016.01.001.
Lesche, S., Lehmann, D., Nagel, F., Schmid, H.A., Schulz, S., Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94:2 (2009 Feb), 654–661, 10.1210/jc.2008-1919.
McKeage, K., Pasireotide in acromegaly: a review. Drugs 75:9 (2015 Jun), 1039–1048, 10.1007/s40265-015-0413-y.
Modlin, I.M., Bodei, L., Kidd, M., Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract. Res. Clin. Endocrinol. Metab. 30:1 (2016 Jan), 59–77, 10.1016/j.beem.2016.01.002.
Mohamed, A., Blanchard, M.P., Albertelli, M. et al., Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr. Relat. Cancer 21:5 (2014), 691–704.
Moore, S.B., van der Hoek, J., de Capua, A., van Koetsveld, P.M., Hofland, L.J., Lamberts, S.W., Goodman, M., Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells. J. Med. Chem. 48:21 (2005 Oct 20), 6643–6652 (PMID: 16220980).
Moreno, A., Akcakanat, A., Munsell, M.F. et al., Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr. Relat. Cancer 15:1 (2008), 257–266.
Öberg, K., Lamberts, S.W., Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr. Relat. Cancer 23:12 (2016 Dec), R551–R566.
Paragliola, R.M., Corsello, S.M., Salvatori, R., Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 20:1 (2017 Feb), 109–115, 10.1007/s11102-016-0768-4.
Peng, Y., Deng, L., Ding, Y., Chen, Q., Wu, Y., Yang, M., Wang, Y., Fu, Q., Comparative study of somatostatin-human serum albumin fusion proteins and natural somatostatin on receptor binding, internalization and activation. PLoS One, 9(2), 2014 Feb 27.
Petrossians, P., Daly, A.F., Natchev, E. et al., Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr. Relat. Cancer 24:10 (2017 Oct), 505–518, 10.1530/ERC-17-0253.
Pöll, F., Lehmann, D., Illing, S. et al., Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol. Endocrinol. 24:2 (2010), 436–446.
Schmid, H.A., Schoeffter, P., Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80:Suppl. 1 (2004), 47–50.
Silverstein, J.M., Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary 19:5 (2016 Oct), 536–543, 10.1007/s11102-016-0734-1.
Tarasco, E., Seebeck, P., Pfundstein, S., Daly, A.F., Eugster, P.J., Harris, A.G., Grouzmann, E., Lutz, T.A., Boyle, C.N., Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine, 2017 Aug 18, 10.1007/s12020-017-1386-2.
Theodoropoulou, M., Stalla, G.K., Somatostatin receptors: from signaling to clinical practice. Front. Neuroendocrinol. 34:3 (2013 Aug), 228–252, 10.1016/j.yfrne.2013.07.005.
